Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
Source: finance.yahoo.com
Related posts:
Oakland, California's only In-N-Out restaurant closing due to crime
China hits back against Western sanctions
The U.S. Is Shelling Out $2.9 Billion Per Day In Interest And These ETFs Let You Get A Piece Of It
This Is the Most Disappointing Thing About Buying Gas at Costco
Over 50% of CEOs say they’re considering cutting jobs over the next 6 months — and remote workers ma...